Join to access to all OVN content. Join for Free
The Most Common (or NOT) Interview questions and How to Handle Them
Medical Science Liaison interview tips MSL interview questions building therapeutic area knowledge interview anxiety techniques aligning with company values

The Most Common (or NOT) Interview questions and How to Handle Them


Share This Article


Summary

In this episode, Anita Carvalho joins MSL Talk to share invaluable interview tips for aspiring Medical Science Liaisons. Anita emphasizes the importance of thoroughly researching the company and effectively presenting one's resume. She offers strategies for selling oneself during interviews and tackling common challenges, including specific MSL interview questions. The discussion covers building relationships, mastering therapeutic area knowledge, and managing interview anxiety using techniques like the STAR method. Anita also highlights the significance of aligning with company values and proper post-interview etiquette. The episode concludes with closing remarks and gratitude.

Check out my latest podcast with Anita Carvalho, Talent Acquisition Specialist at FerGene. We discuss the most common (and not so common) MSL interview questions and how to handle them.

We discuss:

 What basic interview questions should you expect
 What are some MSL specific interview questions
 What are some “not so” common and even wacky interview questions
 What are behavioral (situational) interview questions and how to handle them

Click for Source
Medical Science Liaison interview tips, MSL interview questions, building therapeutic area knowledge, interview anxiety techniques, aligning with company values

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Explore OVN